Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM).
Publication
, Conference
Middleton, MR; Hamid, O; Shoushtari, AN; Meier, FE; Bauer, TM; Salama, AKS; Kirkwood, JM; Ascierto, PA; Lorigan, P; Mauch, C; Orloff, MM ...
Published in: JOURNAL OF CLINICAL ONCOLOGY
2022
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2022
Volume
40
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Middleton, M. R., Hamid, O., Shoushtari, A. N., Meier, F. E., Bauer, T. M., Salama, A. K. S., … Hassel, J. C. (2022). Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 40).
Middleton, Mark R., Omid Hamid, Alexander Noor Shoushtari, Friedegund Elke Meier, Todd Michael Bauer, April K. S. Salama, John M. Kirkwood, et al. “Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 40, 2022.
Middleton MR, Hamid O, Shoushtari AN, Meier FE, Bauer TM, Salama AKS, et al. Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM). In: JOURNAL OF CLINICAL ONCOLOGY. 2022.
Middleton, Mark R., et al. “Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM).” JOURNAL OF CLINICAL ONCOLOGY, vol. 40, no. 16, 2022.
Middleton MR, Hamid O, Shoushtari AN, Meier FE, Bauer TM, Salama AKS, Kirkwood JM, Ascierto PA, Lorigan P, Mauch C, Orloff MM, Evans TRJ, Abdullah SE, Yuan Y, Mitchell J, Hassel JC. Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM). JOURNAL OF CLINICAL ONCOLOGY. 2022.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2022
Volume
40
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences